First agent to beat aflibercept head-to-head in wet AMD, now racing an NDA filing against a runway that stops short of full commercialization

Ocular Therapeutix is a clinical-stage company developing AXPAXLI, an investigational targeted eye drug for wet age-related macular degeneration that is not yet approved.

AXPAXLI became the first investigational agent to beat aflibercept in a Phase 3 superiority trial for wet AMD, a disease where millions face monthly injections. The thesis resolves on whether FDA accepts the 505(b)(2) NDA on SOL-1 data alone, without SOL-R efficacy, and grants a superiority label reflecting that result. The single-arm-adjacent approval path, submitting one completed trial with a second still running, is the key approval risk, since a demand for SOL-R efficacy data would push the timeline well past current runway.